Skip to main content
Premium Trial:

Request an Annual Quote

EMD Millipore, Sistemic Developing Stem Cell Technology

NEW YORK (GenomeWeb News) – EMD Millipore today said it is jointly developing a microRNA biomarker-based monitoring methodology with Sistemic for the consistent growth of stem cells in EMD Millipore's Mobius CellReady platform.

The Billerica, Mass.-based Life Science division of Merck KGaA said that the partnership leverages Sistemic's microRNA marker detection capabilities and that the markers may be incorporated into a commercial kit for quality control of stem cells in culture.

Robert Shaw, commercial director of EMD Millipore's Stem Cell Initiative, said in a statement that ensuring the consistency and quality of large-scale culture systems is critical to furthering the use of stem cell products in the clinic, and the partnership with Sistemic "will help us continue our efforts toward the commercialization of stem cell processing."

Financial and other terms were not disclosed.

Glasgow, UK-based Sistemic develops miRNA services and kit-based products for the pharmaceutical, biotechnology, and cell therapy markets.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.